Solid lipid nanoparticles (SLNs) are nanoscopic (50–1000 nm) colloidal carriers consisting of
solid lipids. The internal core structure of SLNs is easily adaptable to lipophilic compounds.
One of the potential pharmaceutical nano carriers developed for regulated drug delivery are
solid lipid nanoparticles (SLNs), also known as lipospheres. Solid lipids, especially
physiological lipids, that have been successfully dispersed in an aqueous solution along with a
stabilising agent (surfactant) and co-surfactants that may ensure particular qualities are the
active major constituents of SLNs. These substances can be synthesised in large amounts,
regularly biodegrade, and exhibit high levels of stability. These SLNs are created with
biodegradable components. They should be non-toxic or low in toxicity, have a high surface
area, and release drugs gradually with the fewest probable side effects. In recent years, the
pharmaceutical and medical industries have seen a growth in the use of SLN drug delivery,ultrasonic drug and gene delivery, cancer chemotherapy, targeted brain drugs delivery,
delivering peptides and proteins, and cosmetic and dermatological preparations. The
characteristics of SLN include high stability, decreased toxicity, better bioavailability of
bioactive substances that are weakly water soluble, and protection of pharmaceuticals that are
entrapped from sensitive environments. Solvent-based, non-solvent, and other preparation
methods are used to create the SLN. SLNs have been created for a variety of uses, including
pharmacological, biological, cosmetic, and nutraceutical ones. Solid lipid nanoparticles
(SLNs), which are nontoxic, biocompatible, and simple to make, could be able to help.
Keywords: Solid lipid nanoparticles, drug delivery, nonsolvent method
Publication date: 01/12/2024
https://ijbpas.com/pdf/2024/December/MS_IJBPAS_2024_8562.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.12.8562
